Why the study?
Does the inclusion of vWF:collagen-binding activity (CB) in test panels reduce diagnostic errors in the identification of von Willebrand disease compared to vWF:RCo alone?
Population
49 participant laboratories from Australia, New Zealand, and Southeast Asia evaluating 43 plasma samples for…
Comparison
Comprehensive test panels including von… vs Test panels performing vWF:ristocetin cofactor…
Design
Cross-sectional
Follow-up
8 years
Authors
Loading...
May warrant adding vWF:CB to vWD panels to cut misclassification; hypothesis-generating pending prospective validation.
Does the inclusion of vWF:collagen-binding activity (CB) in test panels reduce diagnostic errors in the identification of von Willebrand disease compared to vWF:RCo alone?
Inclusion of vWF:collagen-binding activity in diagnostic test panels substantially reduces error rates in the identification and subtyping of von Willebrand disease.
Favaloro et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: